Drug Profile
Saracatinib - AstraZeneca
Alternative Names: AZD 0530; Saracatinib difumarateLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Baylor College of Medicine; Brigham and Women's Hospital; Icahn School of Medicine at Mount Sinai; Innovative Medicines Initiative; Loyola University Chicago; National Center for Advancing Translational Sciences; National Jewish Health; NHS National Services Scotland; Royal National Orthopaedic Hospital; Sheffield Teaching Hospitals NHS Foundation Trust; Stanford University; University of Cincinnati; University of Miami; University of Oxford; University of South Florida; VU University Medical Center; Yale University
- Class Analgesics; Antidementias; Antineoplastics; Benzodioxoles; Quinazolines; Small molecules
- Mechanism of Action Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease; Cancer pain; Fibrodysplasia ossificans progressiva; Lymphangioleiomyomatosis
- Phase I/II Idiopathic pulmonary fibrosis
- Preclinical Non-small cell lung cancer
- No development reported Alcoholism; Parkinson's disease
- Discontinued Bone cancer; Breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-0 development in Parkinson's-disease in United Kingdom (PO, Tablet)
- 08 Apr 2022 Preclinical trials in Non-small cell lung cancer in United Kingdom
- 08 Apr 2022 Pharmacodynamics data from a preclinical trial in non-small cell lung cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR- 2022)